MX2023013777A - Composicion farmaceutica para tratar o prevenir un trastorno relacionado con la administracion de un agente anticancerigeno. - Google Patents
Composicion farmaceutica para tratar o prevenir un trastorno relacionado con la administracion de un agente anticancerigeno.Info
- Publication number
- MX2023013777A MX2023013777A MX2023013777A MX2023013777A MX2023013777A MX 2023013777 A MX2023013777 A MX 2023013777A MX 2023013777 A MX2023013777 A MX 2023013777A MX 2023013777 A MX2023013777 A MX 2023013777A MX 2023013777 A MX2023013777 A MX 2023013777A
- Authority
- MX
- Mexico
- Prior art keywords
- administration
- treating
- pharmaceutical composition
- anticancer agent
- disorder associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
- A61K38/446—Superoxide dismutase (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
- C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
- C12Y115/01001—Superoxide dismutase (1.15.1.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021083610 | 2021-05-18 | ||
| PCT/JP2022/020473 WO2022244757A1 (ja) | 2021-05-18 | 2022-05-17 | 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013777A true MX2023013777A (es) | 2023-12-04 |
Family
ID=84141593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013777A MX2023013777A (es) | 2021-05-18 | 2022-05-17 | Composicion farmaceutica para tratar o prevenir un trastorno relacionado con la administracion de un agente anticancerigeno. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240261375A1 (https=) |
| EP (1) | EP4353251A4 (https=) |
| JP (1) | JP7504367B2 (https=) |
| KR (1) | KR102843447B1 (https=) |
| CN (1) | CN117279657A (https=) |
| AU (1) | AU2022278242B2 (https=) |
| CA (1) | CA3220333A1 (https=) |
| CO (1) | CO2023017275A2 (https=) |
| MX (1) | MX2023013777A (https=) |
| TW (1) | TWI867299B (https=) |
| WO (1) | WO2022244757A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025178511A1 (ru) * | 2024-02-21 | 2025-08-28 | Евгений Владимирович ГРИГОРЬЕВ | Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0653670B2 (ja) * | 1985-10-28 | 1994-07-20 | 日研フ−ド株式会社 | 化学療法剤の副作用低減化剤 |
| JPH04135485A (ja) * | 1990-09-28 | 1992-05-08 | Seikagaku Kogyo Co Ltd | 白金錯体及び抗腫瘍剤 |
| JP3232542B2 (ja) | 1993-01-08 | 2001-11-26 | 宇部興産株式会社 | ヒトＣｕ，Ｚｎ型スーパーオキシドジスムターゼ誘導体及びその製造法 |
| JPH08208511A (ja) * | 1995-01-31 | 1996-08-13 | Samu Kenkyusho:Kk | 抗運動ニューロン疾患剤 |
| US6221848B1 (en) * | 1998-05-11 | 2001-04-24 | University Of Pittsburgh | Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy |
| US20020055467A1 (en) | 1998-07-06 | 2002-05-09 | Johansen Teit E. | Novel neurotrophic factors |
| JP2001002585A (ja) * | 1999-06-22 | 2001-01-09 | Ltt Kenkyusho:Kk | レシチン化スーパーオキシドジスムターゼ含有抗線維化剤 |
| JP3792487B2 (ja) | 1999-06-24 | 2006-07-05 | 株式会社Ｌｔｔバイオファーマ | レシチン化スーパーオキシドジスムターゼ含有医薬組成物 |
| JP2003532691A (ja) | 2000-05-05 | 2003-11-05 | ノボ ノルディスク アクティーゼルスカブ | 重症疾患神経障害 |
| JP2002080395A (ja) * | 2000-08-31 | 2002-03-19 | Ltt Institute Co Ltd | 心筋傷害処置剤 |
| ES2375797T3 (es) | 2003-01-21 | 2012-03-06 | Genervon Biopharmaceuticals Llc | Péptidos y compuestos de factores tróficos de motoneuronas y sus procedimientos de utilización. |
| JP4958556B2 (ja) * | 2004-10-12 | 2012-06-20 | 株式会社Ｌｔｔバイオファーマ | レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法 |
| WO2006050211A2 (en) | 2004-10-28 | 2006-05-11 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain |
| JP2006169128A (ja) | 2004-12-13 | 2006-06-29 | Ltt Bio-Pharma Co Ltd | 熱傷治療剤 |
| JP4867540B2 (ja) | 2006-09-20 | 2012-02-01 | 日本精工株式会社 | 無段変速装置 |
| US20100143321A1 (en) * | 2006-12-19 | 2010-06-10 | Ltt Bio Pharma Co., Ltd. | Therapeutic composition for interstitual pneumonia |
| JP5459827B2 (ja) | 2009-03-13 | 2014-04-02 | 株式会社Ｌｔｔバイオファーマ | 慢性閉塞性肺疾患改善剤 |
| EP2637698B1 (en) | 2010-11-09 | 2022-04-20 | Novo Nordisk A/S | Double-acylated glp-1 derivatives |
| US9187509B2 (en) | 2012-01-05 | 2015-11-17 | Pled Pharma AB | Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment |
| JP6545926B2 (ja) * | 2012-11-30 | 2019-07-17 | 株式会社ナノエッグ | 手足症候群治療用組成物 |
| RU2017106172A (ru) | 2014-07-31 | 2018-08-28 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn) |
| EP2985036A3 (en) | 2014-08-14 | 2016-03-09 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | CYP2J2 antagonists in the treatment of pain |
| US11197862B2 (en) | 2015-07-16 | 2021-12-14 | Xomics Biopharma, Inc. | Methods of preventing toxicity of platinum drugs |
| JP6650612B2 (ja) | 2015-10-06 | 2020-02-19 | パナソニックＩｐマネジメント株式会社 | 照明制御装置及び照明システム |
-
2022
- 2022-05-17 CN CN202280033165.1A patent/CN117279657A/zh active Pending
- 2022-05-17 JP JP2023522667A patent/JP7504367B2/ja active Active
- 2022-05-17 US US18/560,442 patent/US20240261375A1/en active Pending
- 2022-05-17 EP EP22804668.6A patent/EP4353251A4/en active Pending
- 2022-05-17 CA CA3220333A patent/CA3220333A1/en active Pending
- 2022-05-17 WO PCT/JP2022/020473 patent/WO2022244757A1/ja not_active Ceased
- 2022-05-17 AU AU2022278242A patent/AU2022278242B2/en active Active
- 2022-05-17 MX MX2023013777A patent/MX2023013777A/es unknown
- 2022-05-17 KR KR1020237038088A patent/KR102843447B1/ko active Active
- 2022-05-18 TW TW111118516A patent/TWI867299B/zh active
-
2023
- 2023-12-14 CO CONC2023/0017275A patent/CO2023017275A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4353251A1 (en) | 2024-04-17 |
| CN117279657A (zh) | 2023-12-22 |
| US20240261375A1 (en) | 2024-08-08 |
| JP7504367B2 (ja) | 2024-06-24 |
| AU2022278242B2 (en) | 2024-11-14 |
| CO2023017275A2 (es) | 2023-12-20 |
| TW202313100A (zh) | 2023-04-01 |
| WO2022244757A1 (ja) | 2022-11-24 |
| KR20240008844A (ko) | 2024-01-19 |
| JPWO2022244757A1 (https=) | 2022-11-24 |
| BR112023024140A2 (pt) | 2024-02-06 |
| TWI867299B (zh) | 2024-12-21 |
| AU2022278242A1 (en) | 2023-11-30 |
| EP4353251A4 (en) | 2025-05-14 |
| KR102843447B1 (ko) | 2025-08-06 |
| CA3220333A1 (en) | 2022-11-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023000848A1 (es) | Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer | |
| MX2024008464A (es) | Conjugados de ligando-farmaco (adcs) con grupos escindibles enzimaticamente. | |
| BR112020017090A8 (pt) | Imunoterapias relacionadas com microbioma | |
| MY208750A (en) | Pharmaceutical composition comprising parp inhibitors | |
| BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
| MX2022016422A (es) | Inhibidores de glicolato oxidasa para el tratamiento de enfermedades. | |
| EP4335517A3 (en) | Administration and dosage of diaminophenothiazines | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| ZA202302155B (en) | Interferon-based cancer treatment method and pharmaceutical composition | |
| MX2022009682A (es) | Composicion farmaceutica que contiene regorafenib y un agente estabilizante. | |
| MX2025007174A (es) | Dispersion solida de un inhibidor de her2 | |
| PH12016501527A1 (en) | Pharmaceutical composition comprising diamino heterocyclic carboxamide compound as active ingredient | |
| BR112022007998A2 (pt) | Novo composto e composição farmacêutica para prevenção ou tratamento de câncer que compreende os mesmos | |
| ZA202301066B (en) | Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer | |
| MX2023013777A (es) | Composicion farmaceutica para tratar o prevenir un trastorno relacionado con la administracion de un agente anticancerigeno. | |
| BR112017014189A2 (pt) | terapia de câncer com um parvovirus combinado com bevacizumabe | |
| WO2018097570A3 (ko) | 다파글리플로진 l-프롤린을 포함하는 약제학적 제제 | |
| UY33203A (es) | Medicamento que suprime (o mitiga) varios síntomas neurológicos originados por un trastorno del nervio periférico inducido por un agente anticancerígeno | |
| MX2021002818A (es) | Métodos para tratar el cáncer mediante la inhibición de la enzima conjugadora de ubiquitina e2 k (ube2k). | |
| MX2017013281A (es) | Metodos para tratar transtornos del almacenamiento lisosomal. | |
| BR112022026558A2 (pt) | Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo | |
| BR112017023834A2 (pt) | moduladores seletivos da atividade do receptor gpr55: derivados de cromenopirazole | |
| PH12023553121A1 (en) | Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient | |
| PH12022552013A1 (en) | Novel medicament for treating hepatic encephalopathy |